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Abstract
Background: Most BRCA1 or BRCA2 mutation carriers have inherited a single (heterozygous) mutation.
Transheterozygotes (TH) who have inherited deleterious mutations in both BRCA1 and BRCA2 are rare, and the
consequences of transheterozygosity are poorly understood.
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Methods: From 32,295 female BRCA1/2 mutation carriers, we identified 93 TH (0.3 %). “Cases” were defined as TH,
and “controls” were single mutations at BRCA1 (SH1) or BRCA2 (SH2). Matched SH1 “controls” carried a BRCA1
mutation found in the TH “case”. Matched SH2 “controls” carried a BRCA2 mutation found in the TH “case”. After
matching the TH carriers with SH1 or SH2, 91 TH were matched to 9316 SH1, and 89 TH were matched to 3370
SH2.
Results: The majority of TH (45.2 %) involved the three common Jewish mutations. TH were more likely than SH1
and SH2 women to have been ever diagnosed with breast cancer (BC; p = 0.002). TH were more likely to be
diagnosed with ovarian cancer (OC) than SH2 (p = 0.017), but not SH1. Age at BC diagnosis was the same in TH vs.
SH1 (p = 0.231), but was on average 4.5 years younger in TH than in SH2 (p < 0.001). BC in TH was more likely to be
estrogen receptor (ER) positive (p = 0.010) or progesterone receptor (PR) positive (p = 0.013) than in SH1, but less
likely to be ER positive (p < 0.001) or PR positive (p = 0.012) than SH2. Among 15 tumors from TH patients, there
was no clear pattern of loss of heterozygosity (LOH) for BRCA1 or BRCA2 in either BC or OC.
Conclusions: Our observations suggest that clinical TH phenotypes resemble SH1. However, TH breast tumor
marker characteristics are phenotypically intermediate to SH1 and SH2.
Keywords: Hereditary breast and ovarian cancer, Transheterozygosity, BRCA1, BRCA2
Background
Women who have inherited mutations in BRCA1 or
BRCA2 are at greatly increased risk of developing breast
cancer (BC) and ovarian cancer (OC) [25, 38]. Identifica-
tion of a mutation at these loci can lead to risk or mortality
reduction if optimal surveillance, risk-reducing mastec-
tomy (RRM), and risk-reducing salpingo-oophorectomy
(RRSO) are applied [8, 29]. In addition, treatment of
cancers in mutation carriers has advanced with the
development of PARP inhibitors, which take advantage of
the loss of BRCA1/2 function in tumors [37]. BRCA1 and
BRCA2 are tumor suppressor genes, and tumors from the
majority of mutation carriers have loss of heterozygosity
(LOH), with loss of the normal allele, so there is no
functioning protein [6, 7, 13, 31]. In early studies, including
a small number of tumor samples obtained from large BC
and OC families, it was suggested that greater than 85 % of
BRCA1- or BRCA2-associated cancers exhibited LOH, and
all showed loss of the normal allele.
The vast majority of BRCA1 and BRCA2 mutation
carriers are single heterozygotes for BRCA1 (SH1) or
BRCA2 (SH2). Homozygosity of missense alleles at
BRCA2 (FANCD1) leads to Fanconi Anemia and increased
cancer susceptibility, notably hematological malignancies
[15, 22]. At least three Fanconi Anemia cases are attribut-
able to BRCA2/FANCD1 homozygous mutations [22].
Observations of homozygosity or compound heterozygos-
ity at BRCA1 are very rare. Domchek et al. [9] reported a
female patient with short stature, microcephaly, develop-
mental delay, significant toxicity from chemotherapy, and
epithelial ovarian carcinoma diagnosed at age 28 years.
This woman was a compound heterozygote at BRCA1,
with mutations c.2457delC (p.Asp821Ilefs*25) and
c.5207 T > C (p.Val1736Ala). Both of these mutations are
likely to be deleterious variants in BRCA1-associated can-
cer. The only other reported case of biallelic BRCA1 mu-
tations was in a woman with multiple congenital
anomalies consistent with a Fanconi anemia-like disorder
and breast cancer at age 23 [30].
Transheterozygosity (TH) is the state of heterozygosity
at two different loci. Here, we define TH to be
inheritance of deleterious mutations in both BRCA1 and
BRCA2. Reports on several BRCA1/2 transheterozygotes
(TH) have been reported in the literature, mainly
without further details on tumor or patient phenotype.
Ramus et al. [27] reported on one TH who had been
diagnosed with both BC and OC, and was identified as
having a mutation in BRCA1 c.68_69delAG (185/
187delAG) and BRCA2 c.5946delT (6174delT). LOH in
these tumors was not found. Additional reports identi-
fied TH for BRCA1 c.2389G > T and BRCA2 c.3068dupA
[21], BRCA1 c.68_69delAG and a BRCA2 c.5946delT
[36], and TH with BRCA1 c.68_69delAG and BRCA2
c.5946delT [11] in four cases. In addition, a number of
reports of TH with LOH in cancer samples have been
published. Randall et al. [28] reported one TH identified
with a BRCA1 c.3770_3771delGA and BRCA2 c.5946delT,
and being affected with both BC and OC. For the BC, only
LOH at the BRCA1 locus was found (not at BRCA2), and
the OC sustained LOH at both BRCA1 and BRCA2.
Tesoriero et al. [35] reported a TH with BRCA1
c.3770_3771delGA and BRCA2 c.5946delT. The BC of
this patient lost the wild-type BRCA2 allele. Bell et al. [1]
reported on a TH with c.5266dupC BRCA1 and
c.5946delT BRCA2 mutation having three independent
BCs. They showed that LOH occurred in two BRCA2 and
one BRCA1 tumor. A large clinic-based series of 1191
carriers from Israel [20] identified 16 TH females, 14 with
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the c.68_69delAG BRCA1 and c.5946delT BRCA2
mutations and two with the c.5266dupC BRCA1 and
c.5946delT BRCA2 mutations. A study from Germany
identified eight female TH from 8162 BC/OC families and
compared the clinical characteristics of the TH to their
SH relatives and to SH in the family-based study [14].
To characterize the nature of TH and clinical pheno-
types of TH, we used the Consortium of Investigators of
Modifiers of BRCA1/2 (CIMBA) dataset of 32,295
female BRCA1/2 mutation carriers ascertained in high-
risk clinics and population-based studies. From this
dataset, we investigated the occurrence of TH, we
compared the characteristics and features of BC and OC
in TH and single BRCA1 or BRCA2 mutations, and we
examined LOH in as many cancer samples as possible.
Methods
Study sample
Details of CIMBA participating centers and data collection
have been reported previously [5]. All the included muta-
tion carriers participated in clinical and research studies at
the host institutions after providing informed consent
under IRB-approved protocols. Fifty-five centers and mul-
ticenter consortia (Additional file 1: Table S1) submitted
data that met the CIMBA inclusion criteria [5]. Only
female carriers with pathogenic BRCA1/2 mutations,
concerning TH, SH1, and SH2 mutation carriers, were in-
cluded in the current analysis. Pathogenicity of mutation
was defined as follows: 1) generating a premature termin-
ation codon (PTC), except variants generating a PTC in
exon 27 after codon 3010 of BRCA2; 2) large in-frame
deletions that span one or more exons; and 3) deletion of
transcription regulatory regions (promoter and/or first
exon) expected to cause lack of expression of mutant
allele. We also included missense variants considered
pathogenic by using multifactorial likelihood approaches
[4, 12]. Mutations that did not meet the above criteria but
have been classified as pathogenic by Myriad Genetics,
Inc. (Salt Lake City, UT, USA) were also included.
Mutations are described using the Human Genome Vari-
ation Society (HGVS) nomenclature (http://www.HGVS.org/
varnomen) where the nucleotide numbering is from the A of
the ATG translation initiator codon. For deletions or
insertions, the most 3′ position possible was arbitrarily
assigned as the altered nucleotide. The description of
mutations of all types is given at the genomic level
(using cDNA reference sequences NM_007294.3/
BRCA1 and NM_000059/BRCA2). BIC nomenclature
was also presented for common variants that are familiar
to many researchers and clinicians by their BIC designa-
tion (http://research.nhgri.nih.gov/bic). For BIC nomen-
clature, cDNA sequences were used as reference sequence
(Genbank: U14680/BRCA1 and NM_000059.1/BRCA2).
The nucleotide numbering is from nucleotide 1 of the
cDNA gene sequence and for deletions or insertions the
most 3′ position possible was arbitrarily assigned as the
altered nucleotide.
In order to compare the TH with SH1 and SH2
mutation carriers on phenotypes of interest, we created
a matched case–control set, in which “cases” were de-
fined as TH, and “controls” were SH1 and SH2 mutation
carriers. Matched SH1 “controls” carried a BRCA1 mu-
tation found in the TH “case”. Matched SH2 “controls”
carried a BRCA2 mutation found in the TH “case”. SH1
and SH2 were not matched to TH for any other charac-
teristics. Using this approach, we identified 91 TH and
9316 matched SH1 mutation carriers, and 89 TH and
3370 matched SH2 mutation carriers.
Loss of heterozygosity
From 10 TH individuals, tumor tissue was available from
twelve tumors, and blood DNA from 10 TH. From one
case, tumor tissue from both BC and OC was available,
and from another case affected with bilateral BC, tumor
samples were available from both breast tumors.
Hematoxylin and eosin (H&E) slides from each tumor
were examined by a specialist pathologist. Areas of
>80 % tumor cells were marked for macro-dissection.
DNA from two 10-micron unstained slides was ex-
tracted using the Qiagen QIAmp DNA FFPE Tissue Kit
using the standard protocol but with 500 μl deparaffini-
zation solution.
We performed micro-satellite analysis to objectively
detect LOH as described previously [16]. We amplified
patient tumor and blood DNA for two markers within
BRCA1 (D17S855 and D17S1322) and four markers
around BRCA2 (D13S290, D13S260, D13S1698, and
D13S171). The heterozygosity for these markers ranged
from 0.46 to 0.82 [17, 26]. Primer sequences and dis-
tance from BRCA1 or BRCA2 are given in Additional
file 1 (Table S2). After polymerase chain reaction (PCR)
amplification, samples were size-separated on a 96 capil-
lary DNA analyzer (Applied Biosystems 3730xl). Data
were analyzed using Genemapper Software (Applied
Biosystems). For micro-satellites that were heterozygous,
the ratios of allele peak heights for each tumor sample
were compared to the allele peak heights for the blood
DNA sample using the following formula L = (at2 X
an1)/(at1 X an2), where L = the ratio; a = the height of
the peak; n1 and n2 = normal allele 1 and normal allele
2; t1 and t2 = tumor allele 1 and tumor allele 2. All ten
cases were informative for at least one marker in
BRCA1. Where cases were informative for both markers,
the LOH data were consistent for the two nearby
markers. All ten cases were also informative for at least
one of the four markers in BRCA2. In two cases, the
data were not consistent across all markers in the
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1.74 MB region and the data for the marker closest to
BRCA2 was used.
To complement the information obtained from micro-
satellite analysis, we also undertook DNA sequence
analysis. For each individual, a small region (<200 bp)
around each of their two mutations was PCR-amplified
from both tumor and blood DNA. DNA from peripheral
blood of a healthy control individual was also amplified
for each fragment as a control for no mutation. We used
10 ng of DNA in the PCR reaction, using standard
protocol and primer sequences (given in Additional file 1:
Table S3). All three samples for each mutation were then
treated with EXO-SAP-IT (Affymetrix) and Sanger
sequenced using standard methods [32]. This sequencing
was used to confirm the presence of each mutation in the
blood DNA from the patient and not in the control
sample. We also assessed the mutation status in the tumor
to determine if LOH had occurred. Since we extracted
areas of >80 % tumor cells, both alleles can be present
even when LOH is present, due to contaminating normal
tissue. Therefore, for each tumor we determined for each
mutation if the two alleles were at an equal ratio
compared to the germline sample or if there was a
decrease in one of the two alleles.
Statistical Analysis
For comparison of TH and SH mutation carriers, con-
tingency table analysis using a chi-square test was used
for dichotomous variables, and a t test for continuous
variables. Fisher’s exact tests were used if sample sizes in
any contingency table cell were less than five. Analyses
were done in STATA, v. 13.1.
Results
Characteristics of TH versus SH1 and SH2 mutation carriers
Table 1 describes the 93 female TH from 84 families
identified from the CIMBA database. Among the
matched TH-SH1/SH2 sets, 25 had no cancer diagnosis.
The average age of these women was 39 years and the
average age at diagnosis of BC was 41 years. Only 16
women were less than age 41 and 9 women were over
age 41 at the time of diagnosis (mean age 49.9, range
41.4–67.9). Table 2 shows that OC age for the matched
BRCA1 TH cases was 51.1 years and SH1 controls was
50.9 years (p = 0.154). For the matched BRCA2 set the
average OC age for the TH cases was 54.7 years and for
SH2 controls was 56.8 years (p = 0.421) (Fig. 1).
The most common TH involved inheritance of two of
the three common Jewish mutations: 5 (5.4 %) women
inherited BRCA1 c.5266dupC and BRCA2 c.5946delT;
31 (33.3 %) women inherited BRCA1 c.68_69delAG and
BRCA2 c.5946delT. Six (6.5 %) women carried one of
the three common Jewish mutations and another muta-
tion. The majority of the remaining TH were observed
only once. The majority of the TH self-identified as non-
Hispanic Caucasian or Jewish. Of the 6907 women who
carried one of the Jewish founder mutations, 2732
(39.6 %) self-identified as Jewish, 947 (13.7 %) were un-
known, and 3225 (46.7 %) reported an ethnicity other
than Jewish. We observed two TH in Hispanics and six
TH in Asians (four of which were Korean). Of the 93 TH,
51 were diagnosed with BC only, 4 with OC only, 13 with
both BC and OC, and 25 with no cancer diagnosis.
The matched datasets included 91 TH and 9316 SH1 for
the BRCA1 matched analysis, and 89 TH and 3370 SH2
for the BRCA2 matched analysis. Two BRCA1 mutations
were observed among the TH in our dataset that were not
observed among SH1 (c.1390delA and c.3196G >T), and
four BRCA2 mutations were observed in the TH dataset
that were not observed among the SH2 (c.8633-?_8754
+ ?amp, c.739_740delAT, c.5380delG, and c.2269A >T).
These six carriers were not included in the analysis (de-
noted by asterisk in Table 1). TH were more likely to be
born more recently (i.e., since 1961) than SH2 mutation
carriers but not when compared to SH1s (Table 2). The
TH group consisted of more individuals from Asian ances-
try compared to the SH1 and SH2 groups, with an excess
of women having a Jewish ancestry vs. the SH1 group. TH
were more likely to have ever been diagnosed with BC than
SH1 or SH2 individuals (68.1 % vs. 52.0 %; p = 0.002, and
67.4 % vs. 50.4 %; p = 0.002), and TH were more likely to
be diagnosed with OC than SH2 women (16.9 % vs. 9.3 %;
p = 0.017), which was not observed in TH vs. SH1 women,
perhaps due to the lower incidence of OC in BRCA2 vs.
BRCA1. Age at BC diagnosis was significantly different for
TH vs. SH2 (40.5 years vs. 45.0 years; p < 0.001), but there
was no difference between TH and SH1.
There were 64 TH cases with BC. Of these, 62 TH
were matched to 4846 SH1s and 60 TH were matched
to 1699 SH2 (Table 3). TH were more likely to have
estrogen receptor (ER)- and progesterone receptor (PR)-
positive BC than SH1s (ER: 42.9 % vs. 24.0 %; p = 0.010;
PR: 40.6 % vs. 20.0 %; p = 0.013). In contrast, the BCs of
TH were less likely ER- and PR-positive than in SH2s (ER:
42.9 % vs. 76.5 %; p < 0.0001; PR: 40.6 % vs. 62.8 %; p =
0.012). The proportion of ER- and PR-positive BCs in TH
was intermediate to that of SH1 and SH2. No difference
was seen regarding the HER2 status between the BCs of
TH and SH1s and SH2s, respectively, although the
available numbers were small. No differences in other BC
characteristics (morphology, grade, stage) were observed.
Only 17 TH were diagnosed with OC, and thus we
had limited data on features of OC to make inferences
regarding differences in TH compared with SH1 or SH2.
No statistically significant differences were observed for
OC traits between TH and SHs (Table 4). Surprisingly,
four borderline tumors were reported in both the SH1
and SH2 groups.
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Table 1 Transheterozygote BRCA1 + BRCA2 mutations in 93 women
BRCA1 mutation BRCA2 mutation N % Breast cancer
only
Ovarian cancer
only
Breast + ovarian
cancer
No cancer Self-identified race/
ethnicity
Country of
ascertainmentHGVS: genomic level HGVS: genomic level
n % n % n % n %
c.-19-?_80 + ?dup c.8633-?_8754 + ?amp* 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Jewish Hungary
c.68_69delAG c.5946delT 31 33.3 13 13.9 1 1.1 3 3.2 14 15.0 Caucasian, Jewish, NR USA, Hungary, Israel
c.68_69delAG c.5722_5723delCT 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian Germany
c.1016delA c.7379_7382delACAA 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Asian USA
c.1390delA* c.658_659delGT 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Hispanic USA
c.1504_1508del5 c.2798_2799delCA 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Asian Korea
c.1504_1508del5 c.462_463delAA 1 1.1 0 0.0 0 0.0 1 1.1 0 0.0 Caucasian Germany
c.1687C > T c.6469C > T 1 1.1 0 0.0 0 0.0 1 1.1 0 0.0 Caucasian Italy
c.1793 T > ? c.8537_8538delAG 1 1.1 0 0.0 0 0.0 1 1.1 0 0.0 Caucasian USA
c.181 T > G c.1318_1319dupCT 3 3.2 1 1.1 0 0.0 0 0.0 2 2.2 Caucasian Austria
c.211A > G c.4380_4381delTT 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian UK
c.212 + 1G > A c.739_740delAT* 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian Spain
c.213-12A > G c.7180A > T 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian Italy
c.2389G > T c.3068dupA 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian Canada
c.2405_2406delTG c.4284dupT 1 1.1 0 0.0 0 0.0 1 1.1 0 0.0 Caucasian Italy
c.246delT c.517-2A > G 2 2.2 1 1.1 0 0.0 0 0.0 1 1.1 Caucasian UK
c.301 + 1G > A c.5682C > G 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian USA
c.3048_3052dup5 c.2830A > T 2 2.2 1 1.1 0 0.0 0 0.0 1 1.1 NR Sweden
c.3155delA c.3160_ 3163delGATA 2 2.2 1 1.1 0 0.0 0 0.0 1 1.1 Caucasian Australia
c.3196G > T* c.658_659delGT 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian Germany
c.3228_3229delAG c.3689delC 1 1.1 0 0.0 0 0.0 0 0.0 1 1.1 Caucasian UK
c.3228_3229delAG c.9253dupA 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian Italy
c.3400G > T c.2808_2811delACAA 2 2.2 1 1.1 0 0.0 0 0.0 1 1.1 Caucasian UK
c.3477_3480 delAAAG c.9401delG 1 1.1 0 0.0 1 1.1 0 0.0 0 0.0 Caucasian Italy
c.3627dupA c.6724_6725delGA 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Asian Korea
c.3700_3704del5 c.681 + 1G > A 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian Australia
c.3700_3704del5 c.1815dupA 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian Germany
c.3756_3759delGTCT c.7757G > A 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian USA
c.3759_3760delTA c.9699_9702 delTATG 1 1.1 0 0.0 0 0.0 1 1.1 0 0.0 Hispanic USA
c.3770_3771delAG c.5946delT 2 2.2 1 1.1 0 0.0 1 1.1 0 0.0 NR, Jewish Australia, USA
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Table 1 Transheterozygote BRCA1 + BRCA2 mutations in 93 women (Continued)
c.3839_3843 delinsAGGC c.1636delT 2 2.2 0 0.0 1 1.1 0 0.0 1 1.1 NR France
c.390C > A c.3018delA 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Asian Korea
3910delG c.2830A > T 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian Germany
c.3916_3917delTT c.5380delG* 1 1.1 0 0.0 0 0.0 1 1.1 0 0.0 Caucasian Italy
c.4035delA c.658_659delGT 1 1.1 0 0.0 0 0.0 0 0.0 1 1.1 Caucasian Australia
c.4065_4068delTCAA c.5350_5351delAA 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian USA
c.4186-?_4357 + ?dup c.2636_2637delCT 2 2.2 1 1.1 0 0.0 0 0.0 1 1.1 Caucasian UK
c.427G > T c.8730delT 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian Denmark
c.5030_5033 delCTAA c.1399A > T 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Asian Korea
c.5123C > A c.6275_6276delTT 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian Germany
c.5136G > A c.4965delC 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Asian USA
c.5193 + 1delG c.658_659delGT 1 1.1 0 0.0 1 1.1 0 0.0 0 0.0 Caucasian Germany
c.5251C > T c.6753_6754delTT 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian Austria
c.5266dupC c.8364G > A 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian Austria
c.5266dupC c.5946delT 5 5.4 3 3.2 0 0.0 1 1.1 1 1.1 Jewish UK, Israel
c.5266dupC c.4478_4481delAAAG 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian Germany
c.5266dupC c.5645C > A 1 1.1 0 0.0 0 0.0 1 1.1 0 0.0 Caucasian Germany
c.5406 + 664_*8273del c.9748dupT 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian Greece
c.548-?_4185 + ?del c.2269A > T* 1 1.1 0 0.0 0 0.0 1 1.1 0 0.0 Caucasian Germany
c.962G > A c.2231C > G 1 1.1 1 1.1 0 0.0 0 0.0 0 0.0 Caucasian Germany
Total 93 100 51 54.8 4 4.3 13 14.0 25 26.9
Mean age (range) 39.9 (23–67) 59.2 (57–62) 41.9 (26–53) 39.1 (20–68)
*Not included in the matched analysis because one of the mutations found in the TH was not found among the SH1/SH2 carriers
HGVS Human Genome Variation Society, NR not reported
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Table 2 Description of BRCA1, BRCA2, and transheterozygote BRCA1 + BRCA2 mutation carriers
Variable Value BRCA1 + BRCA2 (TH)N(%) BRCA1 (SH1)N(%) P value* P value* BRCA1 + BRCA2 (TH) N(%) BRCA2 (SH2)N(%) P value** P value**
Total matched 91 9316 89 3370
Year of birth <1940
1941–1950
1951–1960
1961–1970
>1970
5 (5.5)
20 (22.0)
21 (22.6)
27 (29.0)
18 (19.8)
886 (9.5)
1628 (17.4)
2607 (28.0)
2409 (25.9)
1779 (19.0)
0.424 (ref)
0.112
0.474
0.153
0.245
5 (5.6)
19 (21.3)
19 (21.3)
27 (30.3)
19 (21.3)
486 (14.4)
735 (21.8)
914 (27.1)
724 (21.5)
511 (15.2)
0.025 (ref)
0.060
0.156
0.005
0.007
Ethnicity White
African American
Asian
Hispanic
Jewish
Other
47 (51.6)
0 (0)
6 (6.6)
1 (1.1)
30 (33.0)
7 (7.7)
5736 (61.6)
20 (0.2)
82 (0.9)
143 (1.5)
1779 (19.1)
1556 (16.7)
<0.001 (ref)
1.00*
<0.001
1.00
0.002
–
45 (50.6)
0 (0)
6 (6.7)
2 (2.2)
29 (32.6)
7 (7.9)
1686 (50.0)
15 (0.4)
66 (2.0)
57 (1.7)
936 (27.8)
610 (18.1)
0.007 (ref)
1.00*
0.004
0.667
0.573
–
Breast cancer No
Yes
29 (31.9)
62 (68.1)
4470 (48.0)
4846 (52.0)
0.002 29 (32.6)
60 (67.4)
1671 (49.6)
1699 (50.4)
0.002
Age of breast cancer Mean (range) 40.4 (23–67) 41.9 (18–82) 0.231 40.5 (23–67) 45.0 (19–82) <0.001
Ovarian cancer No
Yes
74 (81.3)
17 (18.7)
7766 (83.4)
1550 (16.6)
0.603 74 (83.1)
15 (16.9)
3056 (90.7)
314 (9.3)
0.017
Age of ovarian cancer Mean (range) 54.1 (36–66) 50.9 (20–85) 0.154 54.7 (42–66) 56.8 (26–89) 0.421
Bilateral mastectomy No
Yes
58 (63.7)
8 (9.0)
4807 (51.6)
809 (8.7)
0.599 58 (65.2)
8 (9.0)
1856 (55.0)
305 (9.1)
0.646
Prophylactic oophorectomy No
Yes
45 (49.5)
24 (26.4))
3583 (38.4)
2476 (26.6)
0.307 45 (50.6)
24 (27.0)
1388 (41.2)
980 (29.1)
0.272
Follow up age (if no cancer) Mean (range) 39.1 (20–68) 40.5 (18–99) 0.587 39.1 (20–68) 44.1 (18–94) 0.068
*Matched BRCA1 mutation carriers vs BRCA1 + BRCA2 mutation carriers; **matched BRCA2 mutation carriers vs BRCA1 + BRCA2 mutation carriers
Significant p values are shown in bold type
Rebbeck
et
al.Breast
Cancer
Research
 (2016) 18:112 
Page
7
of
19
Loss of heterozygosity
Due to the frequent LOH in SH individuals, we examined
the hypothesis that either BRCA1 or BRCA2 would be lost
in each of the TH individuals due to LOH, and that which-
ever gene was lost could have an impact on their tumor
characteristics. Of the 68 TH individuals with cancer, LOH
analysis of three tumors from two cases had previously
been published by our group using the same methods as
the newly identified cases [27]. In the context of the current
study, 12 additional tumor samples from 10 patients were
analyzed (Table 5). We first used micro-satellite markers
and an objective ratio of peak heights to determine if there
was loss of one of the alleles when an individual was het-
erozygous [3] (Additional file 1: Tables S4 and S5). LOH
analysis with micro-satellite markers normally includes
linkage or segregation data to determine if the normal allele
is lost. Since we did not have samples from other family
members, we performed Sanger sequencing at the position
of the mutations in both germline and tumor samples to
determine which allele was lost. One sample failed for the
sequencing so it was not possible to determine whether the
normal or mutated allele was lost. Some samples showed
loss of the mutant allele, which would suggest random loss.
Tumors that exhibited LOH by micro-satellite analysis but
did not indicate a decrease of the normal allele by sequen-
cing were not considered to exhibit classic LOH. Following
both sets of analyses and including our previously pub-
lished data, one breast tumor (case 8) and one OC (case 2)
showed LOH for BRCA1, two breast tumors (cases 9 and
11) showed LOH of BRCA2, and the remaining tumors
provided no evidence for LOH at either BRCA1 or BRCA2
(Table 5).
Discussion
This study describes the characteristics of TH compared
with SH1 and SH2 mutation carriers and supplements the
existing literature regarding LOH in TH. Previously, 35
female TH individuals have been reported in the literature
in a series of papers [1, 11, 14, 20, 21, 27, 28, 35, 36]. Only
three relatively small studies have so far compared the char-
acteristics of TH to SH women. Lavie et al. [20] reported a
non-significant difference in BC occurrence; seven of the
16 TH women (46.7 %) had a personal history of breast
carcinoma compared with 372 of 926 (40.2 %) carriers of a
single mutation (odds ratio (OR) = 1.3, 95 % confidence
interval (CI) 0.4–4.0) [20]. The mean age at diagnosis in
TH was 44.6 years, compared with 48.1 in SH. In contrast,
Heidemann et al. [14] based on a study of 8 TH individuals
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Fig. 1 Age of breast and ovarian cancer diagnosis by mutation status
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Table 4 Ovarian tumor characteristics of BRCA1, BRCA2, and transheterozygote BRCA1 + BRCA2 mutation carriers
Trait Value BRCA1 + BRCA2 (TH)N(%) BRCA1 (SH1)N(%) P value BRCA1 + BRCA2 (TH)N(%) BRCA2 (SH2)N(%) P value
N 17 1550 15 314
Grade Well differentiated 0 8 (2.8) 0.930 0 4 (6.2) 0.847
Moderately differentiated 1 (25) 60 (20.8) 1 (25) 12 (18.5)
Poorly/undifferentiated 3 (75) 220 (76.4) 3 (75) 49 (75.4)
Stage 1 0 39 (17.4) 0.600 0 6 (13.3) 0.589
2 1 (33.3) 31 (13.8) 1 (33.3) 5 (11.1)
3 2 (66.7) 120 (53.6) 2 (66.7) 28 (62.2)
4 0 34 (15.2) 0 6 (13.3)
Morphology Serous 5 (83.3) 292 (66.8) 0.905 5 (83.3) 71 (73.2) 0.943
Mucinous 0 4 (0.9) 0 2 (2.0)
Endometroid 0 44 (10.1) 0 7 (7.2)
Clear cell 0 6 (1.4) 0 2 (2.0)
Other 1 (16.7) 91 (20.8) 1 (16.7) 15 (15.5)
Behavior Invasive 7 (100) 449 (99.1) 0.803 6 (100) 89 (95.7) 0.604
Borderline 0 4 (0.9) 0 4 (4.3)
Table 3 Breast tumor characteristics of BRCA1, BRCA2, and transheterozygote BRCA1 + BRCA2 mutation carriers
Trait Value BRCA1 + BRCA2
(TH) N(%)
BRCA1
(SH1) N(%)
P value BRCA1 + BRCA2
(TH) N(%)
BRCA2
(SH2) N(%)
P value
N 62 4846 60 1699
HER2 Negative 14 (93.3) 908 (88.7) 1.00 15 (93.8) 274 (86.2) 0.706
Positive 1 (7.7) 116 (11.3) 1 (6.3) 44 (13.8)
PR Negative 19 (59.4) 1260 (80.0) 0.013 19 (59.4) 215 (37.2) 0.012
Positive 13 (40.6) 356 (20.0) 13 (40.6) 363 (62.8)
ER Negative 20 (57.1) 1347 (76.0) 0.010 20 (57.1) 150 (23.5) <0.0001
Positive 15 (42.9) 424 (24.0) 15 (42.9) 487 (76.5)
Nodal status Negative 20 (66.7) 1197 (65.1) 0.854 19 (65.5) 399 (61.3) 0.647
Positive 10 (33.3) 643 (35.0) 10 (34.5) 252 (38.7)
Grade Well differentiated 2 (7.1) 36 (2.3) 0.161 2 (7.1) 36 (6.4) 0.690
Moderately differentiated 8 (28.8) 342 (22.1) 8 (28.8) 207 (36.6)
Poorly/undifferentiated 18 (64.3) 1172 (75.6) 18 (64.3) 322 (57.0)
Stage 0 1 (4.8) 34 (3.6) 0.541 1 (4.6) 48 (13.9) 0.065
1 7 (33.3) 399 (42.2) 7 (31.8) 123 (35.7)
2 13 (61.9) 440 (46.6) 14 (63.6) 124 (35.9)
3 0 (0) 65 (6.9) 0 (0) 36 (10.4)
4 0 (0) 7 (0.7) 0 (0) 14 (4.1)
Morphology Ductal 26 (70.3) 1544 (74.3) 0.345 27 (73.0) 629 (78.8) 0.359
Lobular 3 (8.1) 61 (2.9) 3 (8.1) 70 (8.8)
Medullary 3 (8.1) 173 (8.3) 2 (5.4) 13 (1.6)
Other 5 (13.5) 301 (14.5) 5 (13.5) 86 (10.8)
Number of positive nodes (SD) 2 (6.1) 1.2 (3.4) 0.215 2.1 (6.2) 1.7 (3.9) 0.627
Tumor size (SD) 19.0 (14.9) 18.3 (12.5) 0.775 19.0 (14.9) 19.2 (14.6) 0.932
Significant p values are shown in bold type
ER estrogen receptor, PR progesterone receptor, SD standard deviation
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suggested that TH develop BC at an earlier age and have
more severe disease than those with single heterozygous
BRCA mutation [14]. Zuradelli et al. [39] reported TH, and
provided the possible association between TH and gastric
cancer. Similar to the results from the study by Lavie et al.
on 16 Ashkenazi Jewish female TH [20], we report that TH
were more likely than both SH1 or SH2 to be diagnosed
with BC, which was also observed in our series. In addition
to prior reports, we observed that TH were more likely to
be diagnosed with OC compared with SH2s, but not com-
pared with with SH1s. TH breast tumors were more likely
to be ER-/PR-positive than in SH1, but less likely than in
SH2 patients, without other different tumor or disease
characteristics.
A number of TH had not been diagnosed with cancer by
the time this analysis was completed. Twenty-five TH in
our cohort had no BC or OC diagnosis at the time of
counseling or genotyping. The average age of these TH in-
dividuals was 39.1 years (range 20–68). Of these, 16 (64 %)
were less than 41 years old at the time of study, which is
the average age of BC diagnosis, and 23 (92 %) were youn-
ger than the average age of OC diagnosis (54 years) in the
CIMBA data. Of these 25 unaffected TH women, 7 (28 %)
reported a RRSO compared to 2751 (22.6 %) who under-
went RRSO among the total set of SH controls without BC
or OC (12,154). Two (8.0 %) cancer-free TH underwent bi-
lateral risk-reducing mastectomy compared to 1076 (8.9 %)
SH. In addition, we had missing data for a number of rele-
vant variables that could have impacted some inferences.
For example, of the 62 breast cancers in the TH groups,
only 21 (34 %) reported stage information.
Although this is the largest series of TH women re-
ported to date, the study is still limited in a number of
ways. TH were more likely to be born more recently
(i.e., since 1961) than SH2, but not SH1. Since there is
evidence that birth cohort may have an important effect
on cancer risk [18], the risk associations reported here
may require additional evaluation in the future. The
higher incidence of BC in the TH group versus both
SH1 and SH2 groups, and of OC in the TH vs. the SH2
cohort could be explained by non-random inclusion of
TH in the sample, leading to potential biases in associa-
tions, and this may limit generalizability of the dataset.
Our analyses also do not account for potentially import-
ant confounders and the longitudinal nature of the data
to follow cancer cases from time of testing to either
cancer diagnosis or censoring after risk-reducing
surgery. Furthermore, the great majority of missing data
on cancer features avoids that certain questions may be
appropriately addressed from this type of dataset.
Additional future studies are required to completely
evaluate these clinically important unresolved issues,
and hopefully with the ongoing multinational collaboration
within consortia like CIMBA this will be possible in time.
Table 5 Loss of heterozygosity in tumor tissue
LOH in breast tumor LOH in ovarian tumor
Case Diagnosis Tissue
studied
BRCA1 mutation BRCA2 mutation Micro-satellite
Data
Sequence
data
Inference Micro-satellite
data
Sequence
data
Inference
1 DCIS DCIS c.5136G > A c.4965delC BRCA1, BRCA2 No No LOH
2 Breast Inv Br c.1793 T > A c.8537_8538delAG BRCA2 BRCA1 No LOH
3 Invasive breast Inv Br c.68_69delAG c.5946delT BRCA1 No No LOH
5 Invasive breast DCISb c.181 T > G c.1318_1319dupCT No BRCA2 No LOH
6 L Bilateral breast DCISb c.5251C > T c.6753_6754delTT No No No LOHd
6R Bilateral breast DCISb c.5251C > T c.6753_6754delTT BRCA1 No No LOHd
7 Invasive breast DCISb c.5266dupC c.8364G > A No BRCA1 No LOH
8 Invasive breast DCISb c.3700_3704del5 c.681 + 1G > A BRCA1, BRCA2 BRCA1 BRCA1 LOH
9 Invasive breast DCISb c.68_69delAG c.5946delT BRCA2 BRCA1,
BRCA2
BRCA2 LOH
10 Invasive breast Inv Br c.68_69delAG c.5946delT BRCA1, BRCA2 Failed Failedc
11a Invasive breast Inv Br c.3770_3771delAG c.5946delT a a BRCA2
LOH
12a Breast Inv Br c.68_69delAG c.5946delT a a No LOH
2 Ovary Ov c.1793 T > A c.8537_8538delAG BRCA1 BRCA1 BRCA1 LOH
4 Ovary Ov c.68_69delAG c.5946delT No No No LOH
12a Ovary Ov c.68_69delAG c.5946delT a a No a a No LOH
See also Additional file 1 (Table S5)
aPreviously published, bwith micro-invasion, ccase failed due to no PCR amplification in the sequencing, dno LOH in either the right or left breast tumor
DCIS ductal carcinoma in situ, Inv Br invasive breast cancer, LOH loss of heterozygosity, Ov ovarian cancer
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Differences in breast tumor hormone receptor status
suggest that TH cases developing BC have an intermediate
cancer phenotype between BRCA1 and BRCA2, which
would be consistent with the tumors being driven by loss
of either BRCA1 or BRCA2. We attempted to determine
the frequency of loss of each gene in a subset of cases
where tumor material was available. Previously published
data suggest a high rate of LOH with loss of the normal
allele in the majority of BRCA1 and BRCA2 cases with
strong family history at approximately 80 and 70 years, re-
spectively [24]. However, we did not find loss of either
BRCA1 or BRCA2 in the majority of tumors. The low fre-
quency of LOH was consistent with the results from a pre-
viously published case (case 12) where we did not find
LOH of either gene in either the breast or ovarian tumor
[27]. Three other papers on TH showed LOH with loss of
the normal allele [1, 28, 35]. One potential reason for the
low frequency of LOH in this study could be that seven of
the breast tumor samples were areas of ductal carcinoma
in situ (DCIS) with micro-invasion rather than a region of
the invasive breast tumor. However, we identified two tu-
mors with LOH in these types of samples so this explan-
ation is unlikely to be the major cause of the low rate of
LOH.
The observed ages at diagnosis of BC in TH, SH1, and
SH2, and the distributions of tumor characteristics may
also reveal the interactions of BRCA1 and BRCA2 muta-
tions, which may have implications for modeling the
cancer susceptibility in TH. The observed age distribu-
tions rule out a multiplicative model for the interactions
of BRCA1 and BRCA2 mutations on BC risk. Given the
well-established BC risks for BRCA1 and BRCA2
mutations, a multiplicative model would imply very high
cancer risk at young ages. However, the present study
suggests that ages at BC diagnosis in TH are not signifi-
cantly different from those in BRCA1 mutation carriers.
Therefore, a multiplicative model of cancer risk for BRCA1
and BRCA2 is inconsistent with the current observations.
This observation, combined with the fact that the tumor
characteristics are intermediate to SH1 and SH2, suggests
that an additive model for the joint effects of BRCA1 and
BRCA2 mutations is more plausible. These results could be
used for modeling the cancer risks for TH carriers and
could be incorporated into risk prediction models.
Micro-satellite analysis alone did show a decrease in
one of the two alleles in more of the tumors (6 out of 12
BRCA1 and 5 out of 12 BRCA2); however, the sequen-
cing data suggested that the mutant allele rather than
the normal allele was lost in many of the tumors.
Although the early publications in high-risk families
showed very high rates of LOH, exclusively with loss of
the normal allele, more recently there have been many
publications showing larger numbers of cases with no
LOH [19, 23, 24] and an increasing number of tumors
with loss of the mutant allele [19, 24]. The second hit in
these tumors could be due to a somatic mutation of the
normal chromosome or due to promoter methylation,
rather than LOH. Unfortunately, the amount of material
from these tumors was very limited, and it was not
possible to preform additional experiments to investigate
alternative mechanisms. Methylation of BRCA1 has been
shown to be a mechanism of decreased BRCA1 expres-
sion in sporadic BC [2, 34], although this is less frequent
in BRCA1 carriers [10, 33]. Why the mechanism of LOH
with loss of the normal allele in TH might be different
compared with SH is unclear. Tumor material was only
available in a small proportion of the cases with cancer.
Therefore, it is difficult to interpret the results of the
tumor study more broadly. Despite the small numbers,
we did not find evidence to support the hypothesis that
the tumors would either have LOH of BRCA1 or
BRCA2. The TH breast tumor characteristics, however,
do appear to be intermediate in phenotype to SH1 and
SH2, suggesting some cancers are being driven by inacti-
vation of BRCA1 and some by inactivation of BRCA2.
Additional studies that explore other causes of inactivation
(e.g., methylation or somatic mutation) are warranted.
Conclusions
We report evidence that the BRCA1 mutation in TH
may drive these clinical TH phenotypes based on ele-
vated OC risk in TH vs. SH2 but not SH1, and earlier
age of BC diagnosis in TH vs. SH2 but not SH1. There-
fore, TH may be managed more like BRCA1 mutation
carriers than BRCA2 mutation carriers. In contrast, TH
breast tumor characteristics (e.g., ER/PR status) are
intermediate in phenotype to SH1 and SH2. Future stud-
ies are warranted to understand whether TH should be
managed differently to SH1 or SH2 carriers, and, if so,
to enable individualized counseling and clinical manage-
ment appropriate for TH mutation carriers.
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